Sunday, May 25, 2025 | 04:44 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Biocon

Biocon Biologics gets six-month extension of insulin supply in Malaysia

Biocon Biologics to continue insulin supply in Malaysia through October 2025 as MoH extends existing contract under partnership with Duopharma and Biocon Sdn. Bhd.

Biocon Biologics gets six-month extension of insulin supply in Malaysia
Updated On : 22 May 2025 | 10:12 PM IST

Biocon shares gain 2% as Japan partner launches Ustekinumab biosimilar

Biocon shares rose over 2 per cent after Biocon Biologics' Japanese commercial partner launched Ustekinumab BS Subcutaneous Injection

Biocon shares gain 2% as Japan partner launches Ustekinumab biosimilar
Updated On : 21 May 2025 | 10:40 AM IST

5 products to be launched in 18 mths, US insulin mkt share up: BBL MD & CEO

Achieving 15 per cent year-on-year growth, with nearly four biosimilars with $200 million in revenue, is a big feat, says Tambe

5 products to be launched in 18 mths, US insulin mkt share up: BBL MD & CEO
Updated On : 19 May 2025 | 10:20 PM IST

Nifty Pharma drops 2% after Trump reveals plans to lower US drug cost

The US President has predicted that pharmaceutical prices could drop 30 per cent to 80 per cent in America

Nifty Pharma drops 2% after Trump reveals plans to lower US drug cost
Updated On : 12 May 2025 | 10:34 AM IST

Biocon Q4FY25 results: Consolidated net profit rises 153% to ₹344 crore

Biotech firm Biocon on Thursday said its consolidated net profit surged over two-fold to Rs 344 crore in the fourth quarter ended March 31, 2025 aided by robust sales across business verticals. The company had reported a net profit of Rs 136 crore in the January-March period of the preceding fiscal. Total revenue rose to Rs 4,454 crore in the latest fourth quarter as compared to Rs 3,966 crore in the year-ago period, Biocon Ltd said in a statement. For the year ended March 31, 2025, the company said its net profit declined to Rs 1,013 crore as compared to Rs 1,022 crore in FY24, it added. Total revenue rose to Rs 16,470 crore in FY25 as compared to Rs 15,621 crore recorded in FY24, the company said. "The Biocon Group ended the year with a strong performance across its businesses," Biocon Group Chairperson Kiran Mazumdar-Shaw said. FY25 has been a year of consolidation and transition, she stated. "We are now on a path of accelerating growth with a commitment to innovation, digita

Biocon Q4FY25 results: Consolidated net profit rises 153% to ₹344 crore
Updated On : 08 May 2025 | 9:27 PM IST

Stocks to Watch, May 8: Britannia, Coal India, Dabur, Voltas, RIL, L&T, PNB

Stocks to Watch on May 8, 2025: Here is a list of stocks that will be on investors' and traders' radar on Thursday, May 8, 2025

Stocks to Watch, May 8: Britannia, Coal India, Dabur, Voltas, RIL, L&T, PNB
Updated On : 08 May 2025 | 8:09 AM IST

Biocon Biologics secures multiple market access coverage for Yesintek in US

Biocon Biologics' biosimilar Yesintek is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, and promises a cost-effective treatment

Biocon Biologics secures multiple market access coverage for Yesintek in US
Updated On : 05 May 2025 | 5:28 PM IST

Syngene Q4 results: PAT down 3%, revenue from ops up 11% to ₹1,018 cr

Bains further noted that after a subdued first half, impacted by a sector-wide downturn in US biotech funding, the second half of the year showed signs of recovery

Syngene Q4 results: PAT down 3%, revenue from ops up 11% to ₹1,018 cr
Updated On : 23 Apr 2025 | 11:06 PM IST

Biocon subsidiary secures permission to launch eye medicine Yesafili in US

Agreement enables company to make 'strategic entry' in ophthalmology sector in the US, it says

Biocon subsidiary secures permission to launch eye medicine Yesafili in US
Updated On : 15 Apr 2025 | 3:40 PM IST

Biocon Biologics signs deal, gets market entry for Yesafili in US by 2026

Biocon Biologics on Tuesday said it has inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor used to treat several types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept). Biocon Biologics and Regeneron executed the settlement agreement to dismiss the pending appeal at the US Court of Appeals for the Federal Circuit (USCAFC) and the pending litigation at the US District Court for the Northern District of West Virginia, Clarksburg Division, Biocon Biologics said in a statement. The agreement enables the company, a unit of Biocon Ltd, to launch its product in the US in the second half of 2026 or earlier in certain circumstances, it added. The terms of the settlement are confidential, it stated. "This settlement clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality ..

Biocon Biologics signs deal, gets market entry for Yesafili in US by 2026
Updated On : 15 Apr 2025 | 1:04 PM IST

Biocon subsidiary gets USFDA nod for Everolimus tablets; share zooms 6%

The rise in the Biocon share price came after its wholly-owned unit, Biocon Pharma, received USFDA nod for Everolimus tablets.

Biocon subsidiary gets USFDA nod for Everolimus tablets; share zooms 6%
Updated On : 11 Apr 2025 | 12:21 PM IST

Biocon Biologics gets US FDA nod for Jobevne, expands oncology portfolio

Jobevne works by blocking a protein called VEGF, which helps tumours grow new blood vessels

Biocon Biologics gets US FDA nod for Jobevne, expands oncology portfolio
Updated On : 10 Apr 2025 | 11:49 AM IST

Biocon, Cipla: Nifty Pharma down 6% as US eyes possible tariffs on sector

Adding to the worries of investors, US is looking for possible tariffs on the pharmaceutical goods

Biocon, Cipla: Nifty Pharma down 6% as US eyes possible tariffs on sector
Updated On : 04 Apr 2025 | 1:59 PM IST

Peter Bains steps down as Group CEO of Biocon, to serve Syngene's MD & CEO

Furthermore, Biocon has scheduled a board meeting on April 4 to discuss and approve fundraising for its commercial business

Peter Bains steps down as Group CEO of Biocon, to serve Syngene's MD & CEO
Updated On : 02 Apr 2025 | 5:29 PM IST

Biocon gains 2% on US FDA nod for ANDA Norepinephrine Bitartrate Injection

The company's subsidiary has received approval from the US Food and Drug Administration (US FDA) for its ANDA Norepinephrine Bitartrate Injection USP, 4 mg/4 mL (1 mg/mL) single-dose vial

Biocon gains 2% on US FDA nod for ANDA Norepinephrine Bitartrate Injection
Updated On : 24 Mar 2025 | 2:39 PM IST

Syngene International acquires its first biologics unit in US for $36.5 mn

The facility, equipped with multiple monoclonal antibody (mAbs) manufacturing lines, comes for a deal value of $36.5 million

Syngene International acquires its first biologics unit in US for $36.5 mn
Updated On : 10 Mar 2025 | 11:56 PM IST

Biocon Biologics, Civica partner to expand Insulin Aspart access in the US

Biocon Biologics' own Insulin Aspart drug product for the US is currently under review by the US Food and Drug Administration (FDA)

Biocon Biologics, Civica partner to expand Insulin Aspart access in the US
Updated On : 06 Mar 2025 | 7:31 PM IST

Here's why Biocon share price popped 3% in trade on March 5; details here

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received final approvals for Lenalidomide capsules and Dasatinib tabs from USFDA

Here's why Biocon share price popped 3% in trade on March 5; details here
Updated On : 05 Mar 2025 | 12:14 PM IST

Stocks to Watch, March 5: Adani Wilmar, Coforge, Biocon, Ola Electric, RVNL

Biocon: The company's subsidiary, Biocon Pharma, has received USFDA approvals for Lenalidomide capsules and Dasatinib tablets, and tentative approval for Rivaroxaban tablets

Stocks to Watch, March 5: Adani Wilmar, Coforge, Biocon, Ola Electric, RVNL
Updated On : 05 Mar 2025 | 8:07 AM IST

Biocon launches drug Liraglutide for diabetes, Biolide for obesity in UK

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK. The GLP-1 peptide, Liraglutide, will be marketed in the UK under the brand names Liraglutide Biocon for diabetes and Biolide for chronic weight management, the company said in a statement. The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, earlier this year, making Biocon Ltd the first generics company to obtain approval for gLiraglutide in a major regulated market, it added. "The timely launch will offer healthcare providers and patients affordable access to this drug and help fulfil an unmet need," Biocon CEO and MD Siddharth Mittal said. The company will continue to focus its efforts towards expanding the reach of gLiraglutide into other European markets, the US and select geographies, he added. Glucagon-like peptide-1 (GLP-1) are medications that help lower blood sugar levels and promote weight loss. Liraglutid

Biocon launches drug Liraglutide for diabetes, Biolide for obesity in UK
Updated On : 28 Feb 2025 | 12:22 PM IST